Filing Details
- Accession Number:
- 0000899243-23-015665
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2023-06-15 21:26:16
- Reporting Period:
- 2022-09-19
- Accepted Time:
- 2023-06-15 21:26:16
- Original Submission Date:
- 2023-05-23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777517 | Walmsley G. Graham | C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-09-19 | 400,000 | $26.00 | 400,000 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2023-05-19 | 120,000 | $42.00 | 520,000 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,168 | Direct |
Footnotes
- This Form 4 amendment is being filed solely to correct the original Form 4 filed on May 23, 2023, which inadvertently included the incorrect transaction date of September 19, 2023, due to a clerical error. This amendment corrects the date of the transaction to September 19, 2022.
- The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.